lung cancer drugs

New universal companion diagnostic paves the way for precision oncologyFDA approves new diagnostic test for non-small cell lung cancer.
Atezolizumab for Urothelial Carcinoma and Non-Small Cell Lung CancerHere: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.
Lung cancer drug approvedSoon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC).
FDA approves new indication for GilotrifFDA recently approved a new indication for afatinib (Gilotrif, Boehringer Ingelheim) for patients with squamous cell carcinoma of the lung. The once-daily tablets are now indicated for the treatment of patients with the lung cancer, whose disease has progressed after treatment with platinum-based chemotherapy. Here are the top 6 facts to know about Gilotrif.
FDA expands drug to treat NSCLCFDA has extended approval of crizotinib (Xalkori, Pfizer) for the treatment of certain patients with non-small cell lung cancer (NSCLC).